Τίτλος:
Association of total and neutralizing SARS-CoV-2 spike -receptor binding domain antibodies with epidemiological and clinical characteristics after immunization with the 1st and 2nd doses of the BNT162b2 vaccine
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Data regarding the association of antibody levels elicited after immunization with the BNT162b2 mRNA COVID-19 vaccine with epidemiological and clinical parameters are limited. Methods: We prospectively measured the total (TAbs-RBD) and the neutralizing antibodies (NAbs-RBD) against the receptor binding domain (RBD) of SARS-CoV-2 spike protein in a cohort of 268 Healthcare workers before immunization, 20 days after the 1st dose and 30 days after the 2nd dose of the BNT162b2 vaccine. A statistical analysis for possible association of antibodies’ levels with epidemiological and clinical parameters was performed. Results: The mean age (±SD) of the participants was 45.45 years (±11.93) (range: 24–70 years) and 211 (79.9%) were females. Statistically significant differences were detected regarding both TAbs-RBD and NAbs-RBD between the first and second doses of the vaccine (P < 0.001). The median (IQR) percentage (%) of NAbs-RBD after the 1st dose was 51.07% (31.60%) and after the 2nd dose 95.31% (3.70%) (P < 0.001). The correlation between the TAbs-RBD and NAbs-RBD was after the 1st dose, Spearman's, rho: 0.861 (P < 0.001) and after the 2nd dose rho: 0.989 (P < 0.001). Twenty days after the 1st dose, 56/264 (21.2%) of the participants had low levels of NAbs-RBD, while one month after the 2nd dose all of them had protective levels of NAbs-RBD. After the 2nd vaccine dose, a statistically significant negative association of TAbs-RBD was detected for age (P < 0.001), smoking (P = 0.011), and immunosuppressive medications (P < 0.001), while a positive association was detected for BMI (P = 0.004) and systemic adverse events after immunization (P = 0.001). Conclusion: A significant correlation of TAbs-RBD and NAbs-RBD was detected after both vaccine doses. Older age, smoking, and immunosuppressive medications negatively affected the final antibody level after SARS-CoV-2 immunization. Our findings emphasize the significance of the 2nd vaccine dose especially in the older age groups. © 2021 Elsevier Ltd
Συγγραφείς:
Michos, A.
Tatsi, E.-B.
Filippatos, F.
Dellis, C.
Koukou, D.
Efthymiou, V.
Kastrinelli, E.
Mantzou, A.
Syriopoulou, V.
Εκδότης:
ELSEVIER SCIENCE LTD.
Λέξεις-κλειδιά:
coronavirus spike glycoprotein; SARS-CoV-2 antibody; tozinameran; bnt 162 vaccine; coronavirus spike glycoprotein; neutralizing antibody; spike protein, SARS-CoV-2; virus antibody, adult; adverse outcome; aged; antibody response; Article; Bell palsy; clinical effectiveness; cohort analysis; drug safety; edema; epidemiological data; fatigue; female; fever; headache; health care personnel; hearing impairment; human; immune response; immunization; injection site pain; male; myalgia; prospective study; receptor binding; risk factor; tinnitus; vaccine immunogenicity; virus neutralization; genetics; immunization; middle aged; young adult, Adult; Aged; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Humans; Immunization; Middle Aged; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Young Adult
DOI:
10.1016/j.vaccine.2021.07.067
